<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A strong genetic component of the beta-cell defect of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is undisputed </plain></SENT>
<SENT sid="1" pm="."><plain>We recently developed a modification of the classic hyperglycemic clamp to assess beta-cell function in response to various stimuli (10 mmol/l <z:chebi fb="105" ids="17234">glucose</z:chebi>, additional glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> [GLP]-1, and arginine) </plain></SENT>
<SENT sid="2" pm="."><plain>Subjects at risk for developing type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (impaired <z:chebi fb="105" ids="17234">glucose</z:chebi>-tolerant individuals, women with <z:hpo ids='HP_0009800'>gestational diabetes</z:hpo>, and individuals with a family history of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>) clearly showed a significantly decreased mean secretory response to <z:hpo ids='HP_0000001'>all</z:hpo> secretagogues compared with controls </plain></SENT>
<SENT sid="3" pm="."><plain>We also showed that <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi>-tolerant carriers of the Gly972Arg polymorphism in the insulin receptor substrate 1 have significantly <z:mp ids='MP_0003059'>reduced insulin secretion</z:mp> in response to <z:chebi fb="105" ids="17234">glucose</z:chebi> and arginine but not to GLP-1 </plain></SENT>
<SENT sid="4" pm="."><plain>More remarkably, however, the relative impairment of the different secretory phases varied greatly in the same individual, indicating a substantial <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of <z:hpo ids='HP_0006279'>beta-cell dysfunction</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Specific prominence of this <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> may reflect a specific cellular defect of the beta-cell </plain></SENT>
<SENT sid="6" pm="."><plain>In subjects sharing this pattern of <z:hpo ids='HP_0001425'>heterogeneity</z:hpo>, any underlying genetic variant may be enriched and thus more likely not only to be identified but also to be related to a pathophysiological mechanism </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, we believe that careful clinical characterization of beta-cell function (and dysfunction) is one way of identifying and understanding the genetic factors leading to the insulin secretory failure of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>